Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis?
- PMID: 30674865
- PMCID: PMC6354725
- DOI: 10.12659/AJCR.911521
Progressive Multifocal Leukoencephalopathy in the Absence of Typical Radiological Changes: Can We Make a Diagnosis?
Abstract
BACKGROUND Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infectious disease with high morbidity and mortality. Its incidence in multiple sclerosis (MS) patients has risen since the introduction of disease modifying drugs. In the absence of a specific treatment, the outcome depends heavily on early diagnosis, which illustrates the importance of the role of characteristic brain magnetic resonance imaging (MRI). However, when relying mainly on MRI, the diagnosis of cases with atypical radiological changes may be missed or delayed. CASE REPORT A 32-year-old female diagnosed with elapsing remitting MS in 2009 was started on interferon-beta-1b that was escalated to natalizumab due to progression of the disease. Later, she was shifted to fingolimod as testing for John Cunningham polyoma virus (JCV) antibodies was positive. Three years later, she presented with a 3-week history of progressive walking impairment associated with twitching of her facial muscles and abnormal sensation all over her body that was associated with left hemi-paresis and sensory changes, in addition to truncal ataxia, which was treated with steroids as a relapse of MS. However, the patient continued to deteriorate and developed significant cognitive and behavioral changes. In view of this clinical picture, the diagnosis of PML was raised in spite of her atypical brain MRI features. Treatment with fingolimod was stopped and a sample of her cerebrospinal fluid was sent for JCV DNA analysis, which came back positive at 11 copies/mL. Treatment with mirtazepine and mefloquine was started, but the patient deteriorated further, and MRI showed severe changes consistent with immune reconstitution inflammatory syndrome. Intravenous steroids and intravenous immunoglobulin were given, and within a few weeks, the patient was stabilized and started to gradually improve. CONCLUSIONS In patients at risk for developing PML who present with typical clinical features, testing for JCV DNA is recommended even in the absence of typical radiological findings in order to prevent any delay in the diagnosis.
Conflict of interest statement
Figures

Similar articles
-
[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].Rev Neurol. 2015 Feb 16;60(4):164-8. Rev Neurol. 2015. PMID: 25670046 Spanish.
-
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.Mult Scler. 2023 Feb;29(2):301-306. doi: 10.1177/13524585221137279. Epub 2022 Nov 30. Mult Scler. 2023. PMID: 36451581
-
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620939802. doi: 10.1177/2324709620939802. J Investig Med High Impact Case Rep. 2020. PMID: 32646245 Free PMC article.
-
Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.BMC Neurol. 2019 Oct 31;19(1):263. doi: 10.1186/s12883-019-1493-1. BMC Neurol. 2019. PMID: 31672142 Free PMC article. Review.
-
Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.J Med Case Rep. 2018 Jul 1;12(1):187. doi: 10.1186/s13256-018-1727-7. J Med Case Rep. 2018. PMID: 29960601 Free PMC article. Review.
Cited by
-
Clinically Isolated Brainstem Progressive Multifocal Leukoencephalopathy: Diagnostic Challenges.Am J Case Rep. 2022 Jan 10;23:e935019. doi: 10.12659/AJCR.935019. Am J Case Rep. 2022. PMID: 35001072 Free PMC article.
-
John Cunningham (JC) Virus Encephalitis Without Progressive Multifocal Leukoencephalopathy in a Stem Cell Transplant Patient: A Case Report and Literature Review.Cureus. 2025 Jul 7;17(7):e87464. doi: 10.7759/cureus.87464. eCollection 2025 Jul. Cureus. 2025. PMID: 40772164 Free PMC article.
-
The Use of Antimalarial Drugs against Viral Infection.Microorganisms. 2020 Jan 8;8(1):85. doi: 10.3390/microorganisms8010085. Microorganisms. 2020. PMID: 31936284 Free PMC article. Review.
-
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.Medicina (Kaunas). 2022 Apr 17;58(4):551. doi: 10.3390/medicina58040551. Medicina (Kaunas). 2022. PMID: 35454389 Free PMC article.
References
-
- Martinez AJ, Sell M, Mitrovics T, et al. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract. 1995;191:427–43. - PubMed
-
- Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63. - PubMed
-
- Dworkin MS. A review of progressive multifocal leukoencephalopathy in persons with and without AIDS. Curr Clin Top Infect Dis. 2002;22:181–95. - PubMed
-
- Hodel J, Outteryck O, Dubron C, et al. Aymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. Diagnostic precision with MR imaging. Radiology. 2016;278(3):863–72. - PubMed
-
- Wijburg MT, Witte BI, Vennegoor A, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016;87:1138–45. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources